08/06/2026
Sometimes the cases the Supreme Court doesn't hear matter just as much as the ones it does.
When people think about the Supreme Court, they often think about landmark decisions that reshape the law. What receives less attention are the cases the Court declines to review. Those decisions can still have a significant impact by leaving lower court rulings in place.
A recent example is Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., a patent case the U.S. Supreme Court declined to hear earlier this year. While the Court did not rule on the merits, its decision leaves the Federal Circuit's opinion in place, allowing it to continue influencing how patent law is applied in the pharmaceutical industry.
The case centers on induced patent infringement. In simple terms, induced infringement occurs when one party encourages another to infringe a patent. In the pharmaceutical industry, these issues often arise when a generic manufacturer receives FDA approval to market a drug for certain uses while excluding others that remain protected by patents, a practice commonly known as a "skinny label."
The central question in Hikma was whether communications beyond the FDA-approved label, including marketing materials, educational content, or sales strategies, could support a claim of induced infringement.
By leaving the Federal Circuit's decision intact, the Supreme Court reinforces an important consideration for companies in the pharmaceutical industry: courts may evaluate more than the product label when determining whether induced infringement has occurred. Communications surrounding a product can be just as relevant as the label itself.
The case also highlights a broader principle. Intellectual property law often evolves through appellate court decisions, even when the Supreme Court chooses not to intervene. Those rulings continue to shape how businesses assess risk, develop commercial strategies, and protect innovation.
For companies navigating complex IP and regulatory environments, understanding these developments is an important part of managing intellectual property and supporting long-term business strategy.